Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of APG-1387 injection combined with entecavir in chronic hepatitis B
CTR20200911Phase 2Terminated
- Sponsor
- Ascentage Pharma
- Start
- Jun 2020
- Modality
- Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dasminapant, entecavir in Chronic Hepatitis B (CHB), sponsored by Ascentage Pharma. Started Jun 2020; status: terminated.
02
Drugs
dasminapantentecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20200911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200911.